



Browse A-Z: drugs, treatments, conditions, drug classes or symptoms

Drugs A-Z

Health Professionals

Side Effects Checker

Medical News

Dosage Guidelines

FDA Alerts

Manage your Meds

New Drugs

Mobile Apps

More

FDA Medwatch Alerts

**Mxbbb Issues
Voluntary Nationwide
Recall of Umary Acid
Hyaluronic Due to the
Presence of Diclofenac
and Omeprazole**

New Drug Approvals

**FDA Approves Attruby
(acoramidis) to Reduce
Cardiovascular Death
and Cardiovascular-
Related Hospitalization
in Patients with ATTR-
CM**

Medical News

**Stroke Guidelines
Updated, With Focus
on Women and GLP-1s**

Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.

FDA Approves Attruby (acoramidis) to Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Patients with ATTR-CM

PALO ALTO, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a new type of biopharmaceutical...

2 days ago New Drug Approvals

FDA Grants Accelerated Approval to Ziihera (zanidatamab-hrii) for the Treatment of HER2-Positive Biliary Tract Cancer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) accelerated approval of Ziihera® (zanidatamab-hrii)...

5 days ago New Drug Approvals

UCB Receives U.S. FDA Approval for Bimzelx (bimekizumab-bkzx) as the First IL-17 IL-17F Inhibitor for Adults with Moderate to Severe Hidradenitis Suppurativa

Brussels (Belgium), November 20, 2024 – 07:00 (CET) – UCB, a global biopharmaceutical company, today announced that the U.S. Food...

5 days ago New Drug Approvals

AHA: Muvalaplin Reduces Lipoprotein(a) Levels in Individuals With Cardiovascular Risk

Muvalaplin reduces lipoprotein(a) levels, according to a study published online Nov. 20 in the Journal of the American Medical Association to coincide...

Today News for Health Professionals

RSNA: Levothyroxine Tied to Bone Loss Over Time in Older Adults

Levothyroxine (LT4) use is associated with longitudinal loss of bone mass and density in older adults, according to a study scheduled to be presented at...

Today News for Health Professionals

1999 to 2020 Saw Twofold Increase in Alcohol-Related Mortality in the U.S.

From 1999 to 2020, there was a significant approximately twofold increase in alcohol-related mortality in the United States, according to a study published...

Today News for Health Professionals

COVID-19, Flu, RSV Vaccine Coverage Low for Adults in 2024 to 2025 Season

COVID-19, influenza, and respiratory syncytial virus (RSV) vaccination coverage is low among adults so far this respiratory virus season (2024 to 2025),...

Today News for Health Professionals

Supreme Court Won't Hear Big Tobacco's Challenge to Cigarette Warning Labels

The U.S. Supreme Court on Monday declined to hear a major tobacco company's challenge to a federal law that would mandate graphic images on cigarette packs. Some...

Today Medical

Wildfire Smoke Exposure Linked to Dementia Risk

People in Southern California with relatively high exposures to wildfire smoke over a decade also had significantly higher risks for dementia, a new study...

Today Medical

T-Day Dinner, Post-Election: Experts Offer Tips to Keep Things Calm

Politics, especially the 2024 elections, can quickly turn the family Thanksgiving table into a battleground. Steering clear of hot-button topics will...

Today Medical

Stroke Guidelines Updated, With Focus on Women and GLP-1s

Women, especially those who had high blood pressure during pregnancy or entered menopause before age 45, are among those with a greater risk for stroke. They...

Today Medical

Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas

CHANHASSEN, Minn., Nov. 24, 2024. Alpheus Medical, Inc., a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment...

Today Clinical Trials

Could a Vitamin Be Effective Treatment for COPD?

A daily dose of vitamin B3 reduced inflammation in the lungs of patients with COPD, Danish researchers report. "This is significant, because inflammation...

3 days ago Medical

First Patient Dosed in Clinical Trial of ABI-110, a Groundbreaking Gene Therapy for Wet AMD Including PCV

HAYWARD, Calif., Nov. 21, 2024. Avirmax Biopharma, Inc., a leader in the development of innovative gene therapies, today announced that the first patient...

3 days ago Clinical Trials

Mxbbb Issues Voluntary Nationwide Recall of Umary Acid Hyaluronic Due to the Presence of Diclofenac and Omeprazole

MXBBB is voluntarily recalling 1 lot of UMARY ACID HYALURONIC, 30 CAPLETS 850 MG to the consumer level. The products have been found to have omeprazole...

5 days ago FDA Alerts

Endo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling

Endo, Inc. (OTCQX: NDOI) ("Endo") announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously announced...

6 days ago FDA Alerts

[Read more news...](#)

Recently Added

Recently added consumer and prescribing information: Revuforj, Danziten, Aucatzyl, Emrosi, Imuldosa, Hympavzi, Flyrcado, Otulfi, Tecentriq Hybreza, Pavblu

For Consumers

- Cerner Multum Drug Information
- Micromedex Advanced Consumer
- Natural Product Information for the Consumer

For Professionals

- FDA Professional Information
- Professional Patient Advice
- ASHP Monographs (AHFS DI)
- Micromedex Carenotes
- Natural Product Information

For Researchers

- Pharmaceutical Company Directory

Latest FDA New Drug Approvals

Attruby

Attruby (acoramidis) is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant...

Ziihera

Ziihera (zanidatamab-hrii) is a bispecific HER2-directed antibody for the treatment of HER2-positive biliary tract cancer.

Revuforj

Revuforj (revumenib) is a first-in-class menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine...

[More FDA approvals...](#)

Drugs in Development

(Not yet approved)

Yutrepia

Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil tentatively approved for the treatment of pulmonary arterial...

[More drugs in development...](#)

Do Not Sell or Share My Personal Information

